Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials

BACKGROUND: In statin trials, men and women derived similar relative risk reductions in cardiovascular events per 39 mg/dL low‐density lipoprotein cholesterol (LDL‐C) reduction. We explored whether lower LDL‐C levels and greater LDL‐C percentage reductions than those achieved with statins are associ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Heart Assoc
Main Authors: Vallejo‐Vaz, Antonio J., Ginsberg, Henry N., Davidson, Michael H., Eckel, Robert H., Cannon, Christopher P., Lee, L. Veronica, Bessac, Laurence, Pordy, Robert, Letierce, Alexia, Ray, Kausik K.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6222947/
https://ncbi.nlm.nih.gov/pubmed/30371190
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.118.009221
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados